Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenus Share News (GNS)

Share Price Information for Genus (GNS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,892.00
Bid: 1,896.00
Ask: 1,902.00
Change: 12.00 (0.64%)
Spread: 6.00 (0.316%)
Open: 1,876.00
High: 1,910.00
Low: 1,876.00
Prev. Close: 1,880.00
GNS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Genus shares plunge as expects adjusted profit and revenue decline

Thu, 15th Feb 2024 09:41

(Alliance News) - Genus PLC on Thursday warned that Chinese porcine markets continued to be "challenging", as it anticipates reporting lower revenue and adjusted pretax profit for its recent half-year.

Shares in the Basingstoke, England based animal genetics biotechnology company focused on cattle and pig farms plunged 30% to 1,478.00 pence each on Thursday morning in London.

Genus expects to report adjusted pretax profit for the financial first-half ended December 31 of GBP29 million on revenue of GBP334 million.

Both outcomes will be in line with expectations, but they would represent a 31% slump in adjusted pretax profit from GBP42.2 million a year before and a 4.6% decline on the top line from GBP350.2 million.

"[Pig Improvement Co] ex-China performed robustly, with North America, Latin America and Europe delivering adjusted operating profit growth in constant currency. China continues to be a challenging porcine market, however our enhanced commercial focus has resulted in winning new royalty customers in the period which will positively impact fiscal year 2025 and beyond," Genus added.

PIC sales comprise semen, embryos and breeding animals with 'superior' genetics to those animals currently on farms.

Genus said: "With regards to our PRP programme, recent engagement with the US Food & Drug Administration has shifted to the post-approval compliance procedures. This has clarified the data submissions and monitoring that will be required on an ongoing basis post-PRP approval. Validation of our procedures to comply with these monitoring requirements is expected to take several months. We therefore now expect FDA approval in fiscal year 2025. Our dialogue shifting to the post-approval compliance procedures reinforces our view that approval will be forthcoming. There are no changes to our commercialisation timeline or financial projections."

Genus's PRP programme focuses on pigs who are resistant to porcine reproductive and respiratory syndrome, or PRRS. Genus has developed a solution to protect pigs from the PRRS virus, which causes animal suffering and prematurely kills millions of pigs every year.

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
25 Feb 2021 09:05

Genus reports strong interim results

(Sharecast News) - Animal genetics company Genus reported a record adjusted profit before tax in its interim results on Thursday, as revenue in its porcine genetics business 'PIC' rose 8%.

Read more
18 Feb 2021 15:58

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
18 Jan 2021 11:59

LONDON MARKET MIDDAY: US Holiday Leads To Quiet Session; Airlines Slip

LONDON MARKET MIDDAY: US Holiday Leads To Quiet Session; Airlines Slip

Read more
18 Jan 2021 09:34

UK BROKER RATINGS SUMMARY: Land Securities And Dixons Get Upgrades

UK BROKER RATINGS SUMMARY: Land Securities And Dixons Get Upgrades

Read more
18 Jan 2021 08:40

LONDON MARKET OPEN: Soft Start As China Retail Sales Signal Weakness

LONDON MARKET OPEN: Soft Start As China Retail Sales Signal Weakness

Read more
18 Jan 2021 08:35

Genus Set To Post Strong Interim Growth, Beat Prior Annual Guidance

Genus Set To Post Strong Interim Growth, Beat Prior Annual Guidance

Read more
18 Jan 2021 07:43

LONDON MARKET PRE-OPEN: Spirent Expects Earnings Growth For 2020

LONDON MARKET PRE-OPEN: Spirent Expects Earnings Growth For 2020

Read more
4 Dec 2020 16:06

UK Dividends Calendar - Next 7 Days

UK Dividends Calendar - Next 7 Days

Read more
2 Dec 2020 08:40

Covid-19 vaccines trigger new bullmarket, Liberum says

(Sharecast News) - The development of successful Covid-19 vaccines has set off a fresh bull market for UK shares that will last several years, Liberum analysts said.

Read more
25 Nov 2020 13:38

Wednesday broker round-up

(Sharecast News) - Codemasters Group: Berenberg downgrades to hold with a target price of 485p.

Read more
25 Nov 2020 11:56

LONDON MARKET MIDDAY: Pre-Thanksgiving Markets Lull; Sunak Review Due

LONDON MARKET MIDDAY: Pre-Thanksgiving Markets Lull; Sunak Review Due

Read more
25 Nov 2020 10:44

UK WINNERS & LOSERS SUMMARY: GoCo Up, Future Down After Takeover Offer

UK WINNERS & LOSERS SUMMARY: GoCo Up, Future Down After Takeover Offer

Read more
25 Nov 2020 10:10

Genus Reports Strong Trading Growth Depsite Covid-19 Pandemic Impact

Genus Reports Strong Trading Growth Depsite Covid-19 Pandemic Impact

Read more
25 Nov 2020 09:28

UK BROKER RATINGS SUMMARY: Jefferies Upgrades Antofagasta And Glencore

UK BROKER RATINGS SUMMARY: Jefferies Upgrades Antofagasta And Glencore

Read more
25 Nov 2020 08:31

Genus sees 'good momentum' carry over into new trading year

(Sharecast News) - Animal genetics company Genus said on Wednesday that "good momentum" seen at the end of the previous trading year had carried over into the current one.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.